Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study.
Di Maio M, Bighin C, Schettini F, Ruelle T, Marandino L, Fabi A, De Angelis C, Giuliano M, De Placido P, De Laurentiis M, Riccardi F, Picotto C, Puglisi F, Del Mastro L, Arpino G; Gruppo Italiano Mammella (GIM) Study Group. Di Maio M, et al. Among authors: del mastro l. Breast. 2023 Dec;72:103583. doi: 10.1016/j.breast.2023.103583. Epub 2023 Sep 25. Breast. 2023. PMID: 37783133 Free PMC article.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Bianco AR, et al. Among authors: del mastro l. Ann N Y Acad Sci. 1993 Nov 30;698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x. Ann N Y Acad Sci. 1993. PMID: 8279772 Clinical Trial. No abstract available.
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Venturini M, et al. Among authors: del mastro l. Breast Cancer Res Treat. 2006 Jan;95(1):45-53. doi: 10.1007/s10549-005-9030-x. Breast Cancer Res Treat. 2006. PMID: 16267615 Clinical Trial.
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Viale G, et al. J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3. J Clin Oncol. 2008. PMID: 18981464 Free PMC article. Clinical Trial.
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro L. Venturini M, et al. Among authors: del mastro l. Breast. 2010 Oct;19(5):333-8. doi: 10.1016/j.breast.2010.01.018. Epub 2010 Feb 24. Breast. 2010. PMID: 20185313 Free article. Clinical Trial.
346 results